Business Wire

CA-BERKELEY-SKYDECK

2.8.2022 13:02:06 CEST | Business Wire | Press release

Share
Berkeley SkyDeck Introduces New Tracks Ahead of Open Applications for Next Cohort Class

Berkeley SkyDeck , the global hub for entrepreneurship and leading accelerator, today announced that applications are now open for its 15th cohort class, with a final deadline of August 31, 2022. Applications are available here . Batch 15 cohorts can take advantage of new tracks added in the last year, including the Aero-Astro Track, led by advisor Robin Riedel of McKinsey and Company, and the Blockchain/Crypto Track, led by advisor Linda Kreitzman. Berkeley SkyDeck’s Chip Track also named a new advisor, David Horsley of UC Davis. In addition, Berkeley SkyDeck will launch a CivTech Track in the coming year, in partnership with the Center for Security in Politics at UC Berkeley, with former Secretary of Homeland Security Janet Napolitano leading the track as a primary advisor. In addition to these new tracks, SkyDeck will continue to work with startups in industries that have always been an area of focus for venture investors, including consumer, enterprise software, biotech, greentech and more.

Berkeley SkyDeck accepts just over 1.5% of startups that apply and approximately 20 to 25 startups overall for each of its cohorts. Cohort companies receive $200,000 in funding, $750,000 worth of free and discounted resources, and access to SkyDeck’s unsurpassed network of UC Berkeley alumni, faculty, and advisors. Alumni of Berkeley SkyDeck have enjoyed great success in their respective industries, collectively raising more than $1.7 billion in funding. The recently launched Berkeley SkyDeck Europe is currently working with its first group of cohorts, who will present their own Demo Day on October 20, 2022.

“Our mission at Berkeley SkyDeck is to continue the tradition of excellence in entrepreneurship and innovation that makes UC Berkeley one of the top public universities in the world. Expanding our operations in Europe and opening additional tracks for our cohorts are just a couple examples of how we are striving to meet the needs of founders around the world,” said Caroline Winnett, Executive Director. “I am looking forward to seeing what these batch applicants have to offer – and how we can leverage the university’s vast resources to set them up for success.”

Berkeley SkyDeck’s newest tracks reflect trends in growth and investments. Last year, for example, aerospace startups raised $15.4 billion while US semiconductor and chip investment reached $2.6 billion in 2021 , nearly doubling in just three years. Civtech is also burgeoning, with the industry’s transaction volume rising to $14 billion total in 2021 .

“While Berkeley SkyDeck might be rooted here in Silicon Valley, our reach is global, and we’re excited to see how both homegrown and international startups tackle the issues in their industries across all of our tracks,” said Chon Tang, Founding Partner, Berkeley SkyDeck Fund. “As we evaluate, advise, and potentially invest, we are continually energized by these fresh ideas and new approaches. The SkyDeck Fund is ready and waiting to take these newest cohort companies to the next level.”

In March 2022, Berkeley SkyDeck recently announced the close of the $60 million SkyDeck Fund II, which continues to actively fund companies. The SkyDeck Fund has invested in 160 companies to date, representing a wide range of businesses and industries, from 30 countries around the world. Unlike other VC funds, the SkyDeck Fund shares half of its profits with UC Berkeley, helping to continue the university’s mission of delivering excellence in education.

Berkeley SkyDeck will conduct extensive research on applicants, and will hold interviews between September and October 2022. The six-month program will begin in November 2022, concluding at the end of April 2023. Berkeley SkyDeck will host the cohort’s Demo Day for investors on April 4, 2023.

About Berkeley SkyDeck

Berkeley SkyDeck is a leading accelerator and the global hub for entrepreneurship. As UC Berkeley’s largest and most prominent accelerator, SkyDeck combines hands-on mentorship with the vast resources of its research university. SkyDeck is the only accelerator of its kind that offers the value of a dedicated investment fund alongside the resources and network of a top university. To date, SkyDeck startups have raised more than $1.7 billion in aggregate. Participating startups have access to SkyDeck’s 420 advisors, 70 industry partners, and a network of more than 510,000 UC Berkeley alumni. For more information, see skydeck.berkeley.edu .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 07:00:00 CEST | Press release

Galderma received a Complete Response Letter from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization Relfydess is approved in 33 markets and already launched in more than 20, including across Europe, the Middle East and Australia, with an encouraging early launch trajectory supported by positive healthcare professional feedback Regulatory filings in other territories are ongoing and remain on track Ad hoc announcement pursuant to Art. 53 LR Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufa

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 03:45:00 CEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release

FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye